GENB at a glance
Generate Biomedicines Inc (GENB, SEC CIK 2100782) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Generate Biomedicines Inc (GENB) shares worth $202.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ARNOLD FRANCES on October 29, 2026 of 11,409 shares at $16.19 per share.
- In the last 90 days, GENB insiders reported 0 open-market purchases ($0) and 2 open-market sales ($201K) on Form 4, a net sale of $201K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$201K
- 13F holders
- 22 funds
- $202.8M · +1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material-change statement, but 2026 filing adds Zealand collaboration: $30.0 million upfront payment extends funding into first half of 2028
- Regulatory risk: EU AI Act provisions effective August 2, 2026, imposing data quality, transparency, monitoring and oversight obligations
- Clinical risk: GB-0895 Phase 3 severe-asthma trials use one 300 mg dose despite FDA and EMA dose-ranging recommendations
- Operational risk: GB-0895 transition to autoinjector and pre-filled syringe may require bridging studies or repeat trials
- Financial risk: Nine-month net loss $216.6 million and accumulated deficit $892.7 million as of September 30, 2026
Management Discussion & Analysis
- Collaboration revenue $4.2M, down $5.4M from $9.6M YoY, as Novartis and Amgen obligations near completion
- Net loss $87.7M vs $60.0M YoY, operating margin -2,168.4% vs -651.7% YoY
- GB-0895 highest-spending program, R&D costs $37.1M vs $12.4M YoY; discovery programs lowest at $3.2M vs $10.2M
- Operating cash outflow $193.2M, investing outflow $170.3M, financing inflow $381.8M, including IPO proceeds
- Cash, equivalents and marketable securities $404.2M, funding expected into first half of 2028 including Zealand’s $30.0M upfront payment
AI summary of the GENB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing the company’s detailed results and management commentary
Item EX-99.1: Item EX-99.1
- GB-0895 Phase 3 asthma trials evaluate 300 mg every 26 weeks, with six-month biomarker suppression supporting twice-yearly dosing
- Zealand deal adds $30 million upfront, up to $35 million early milestones, and nearly $1.2 billion potential milestones plus tiered royalties
Item 7.01: Regulation FD Disclosure
- ERS posters disclose ongoing GB-0895 clinical-trial results in severe asthma and COPD
- Data support potential twice-yearly subcutaneous dosing for asthma patients
Item 2.02: Results of Operations and Financial Condition
- Press release announces Generate Biomedicines’ financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 2026 revenue $6.3M, down from $10.1M, signaling lower collaboration activity from Amgen and Novartis
- Net loss $67.3M, versus $56.7M, as R&D increased to $64.3M for Phase 3 asthma investment
AI summaries of GENB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GENB
Don't miss the next GENB filing
- Alerts as it files. A push when GENB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GENB, by share count.
- Ask anything. An AI agent that reads every GENB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| ARNOLD FRANCES | Sell | Oct 29, 2026 | 11,409 | $16.19 |
| ARNOLD FRANCES | Sell | Sep 1, 2026 | 1,000 | $16.00 |
| Nally Michael | Buy | Mar 4, 2026 | 20,000 | $12.00 |
| AFEYAN NOUBAR | Buy | Mar 2, 2026 | 1,562,500 | $16.00 |
| AFEYAN NOUBAR | C | Mar 2, 2026 | 987,491 | - |
| AFEYAN NOUBAR | C | Mar 2, 2026 | 2,777,752 | - |
| AFEYAN NOUBAR | C | Mar 2, 2026 | 13,702,224 | - |
| AFEYAN NOUBAR | Buy | Mar 2, 2026 | 1,562,500 | $16.00 |
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate GENB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $202.8M |
| Q2 2026 | 21 | $258.7M |
| Q1 2026 | 14 | $145.1M |
- JPMorgan Chase & Co+1.25M (+88%)
- Vanguard Capital Management LLC+1.10M (+97%)
- ARK Investment Management+680.0K (+53%)
- Millennium Management+520.0K (+2371%)
- Two Sigma Investments+186.8K (+1017%)
- T. Rowe Price Group−819.2K (-38%)
- Bank of America Corp−29.4K (-53%)
- Citigroup−29.4K (-96%)
- Ameriprise Financial−5.5K (-6%)
- Northern Trust−4.2K (-2%)
- Citadel Advisors LLC+38.3K
- U.S. Bancorp+190
- Fifth Third Bancorp+204
- FMR LLC (Fidelity)−5.22M
- Renaissance Technologies LLC−39.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 57 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GENB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | May 7, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | - | |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
GENB SEC filings: frequently asked questions
Are GENB insiders buying or selling?
In the last 90 days, Generate Biomedicines Inc (GENB) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $200,735 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GENB stock?
As of September 30, 2026, the largest Generate Biomedicines Inc (GENB) holders among the 13F filers tracked by SignalX were JPMorgan Chase & Co ($40.9 million), Vanguard Capital Management LLC ($33.6 million), ARK Investment Management ($29.5 million), BlackRock ($27.5 million), T. Rowe Price Group ($20.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did GENB report in its latest 8-K?
Generate Biomedicines Inc (GENB) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest GENB SEC filings?
Generate Biomedicines Inc (GENB) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 4, 2026.
What is GENB's SEC CIK number?
Generate Biomedicines Inc (GENB)'s SEC Central Index Key (CIK) is 2100782. EDGAR lists every GENB filing under that number.
Ask anything about GENB
The research agent reads GENB's filings, financials, insider trades and 13F holders, then answers with sources.